As a further potential treatment option in the EGFR-mutated NSCLC setting, the role of antibody drug conjugates (ADCs) also deserves to be discussed, with patritumab-deruxtecan and datopotamab-deruxtecan showing response rates of about 30% to 43% in phase 2 trials conducted in heavily pretreated patients harboring actionable gene mutations [33,34,35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.